De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients

M. Cioni, A. Nocera, A. Innocente, A. Tagliamacco, A. Trivelli, S. Basso, G. Quartuccio, I. Fontana, A. Magnasco, F. Drago, A. Gurrado, I. Guido, F. Compagno, G. Garibotto, C. Klersy, E. Verrina, G. M. Ghiggeri, M. Cardillo, P. Comoli, F. Ginevri

Research output: Contribution to journalArticle

Abstract

De novo posttransplant donor-specific HLA-antibody (dnDSA) detection is now recognized as a tool to identify patients at risk for antibody-mediated rejection (AMR) and graft loss. It is still unclear whether the time interval from transplant to DSA occurrence influences graft damage. Utilizing sera collected longitudinally, we evaluated 114 consecutive primary pediatric kidney recipients grafted between 2002 and 2013 for dnDSA occurrence by Luminex platform. dnDSAs occurred in 39 patients at a median time of 24.6 months. In 15 patients, dnDSAs developed within 1 year (early-onset group), while the other 24 seroconverted after the first posttransplant year (late-onset group). The two groups were comparable when considering patient- and transplant-related factors, as well as DSA biological properties, including C1q and C3d complement-binding ability. Only recipient age at transplant significantly differed in the two cohorts, with younger patients showing earlier dnDSA development. Late AMR was diagnosed in 47% of the early group and in 58% of the late group. Graft loss occurred in 3/15 (20%) and 4/24 (17%) patients in early- and late-onset groups, respectively (p = ns). In our pediatric kidney recipients, dnDSAs predict AMR and graft loss irrespective of the time elapsed between transplantation and antibody occurrence.
Original languageEnglish
Pages (from-to)1747030
Number of pages1
JournalJournal of Immunology Research
Volume2017
DOIs
Publication statusPublished - 2017

Fingerprint

Tissue Donors
Transplants
Kidney
Antibodies
Graft Rejection
Complement C3d
Complement C1q
Pediatrics
Transplantation
Serum

Keywords

  • Adolescent
  • Age Factors
  • Child
  • Complement C1q/immunology
  • Complement C3d/immunology
  • Female
  • Graft Rejection/immunology
  • HLA Antigens/immunology
  • Humans
  • Isoantibodies/blood/immunology
  • Kidney Transplantation/adverse effects
  • Longitudinal Studies
  • Male
  • Retrospective Studies
  • Risk Factors
  • Tissue Donors

Cite this

De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients. / Cioni, M.; Nocera, A.; Innocente, A.; Tagliamacco, A.; Trivelli, A.; Basso, S.; Quartuccio, G.; Fontana, I.; Magnasco, A.; Drago, F.; Gurrado, A.; Guido, I.; Compagno, F.; Garibotto, G.; Klersy, C.; Verrina, E.; Ghiggeri, G. M.; Cardillo, M.; Comoli, P.; Ginevri, F.

In: Journal of Immunology Research, Vol. 2017, 2017, p. 1747030.

Research output: Contribution to journalArticle

@article{55b918e5b6394795a09f4d45eaa1b5aa,
title = "De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients",
abstract = "De novo posttransplant donor-specific HLA-antibody (dnDSA) detection is now recognized as a tool to identify patients at risk for antibody-mediated rejection (AMR) and graft loss. It is still unclear whether the time interval from transplant to DSA occurrence influences graft damage. Utilizing sera collected longitudinally, we evaluated 114 consecutive primary pediatric kidney recipients grafted between 2002 and 2013 for dnDSA occurrence by Luminex platform. dnDSAs occurred in 39 patients at a median time of 24.6 months. In 15 patients, dnDSAs developed within 1 year (early-onset group), while the other 24 seroconverted after the first posttransplant year (late-onset group). The two groups were comparable when considering patient- and transplant-related factors, as well as DSA biological properties, including C1q and C3d complement-binding ability. Only recipient age at transplant significantly differed in the two cohorts, with younger patients showing earlier dnDSA development. Late AMR was diagnosed in 47{\%} of the early group and in 58{\%} of the late group. Graft loss occurred in 3/15 (20{\%}) and 4/24 (17{\%}) patients in early- and late-onset groups, respectively (p = ns). In our pediatric kidney recipients, dnDSAs predict AMR and graft loss irrespective of the time elapsed between transplantation and antibody occurrence.",
keywords = "Adolescent, Age Factors, Child, Complement C1q/immunology, Complement C3d/immunology, Female, Graft Rejection/immunology, HLA Antigens/immunology, Humans, Isoantibodies/blood/immunology, Kidney Transplantation/adverse effects, Longitudinal Studies, Male, Retrospective Studies, Risk Factors, Tissue Donors",
author = "M. Cioni and A. Nocera and A. Innocente and A. Tagliamacco and A. Trivelli and S. Basso and G. Quartuccio and I. Fontana and A. Magnasco and F. Drago and A. Gurrado and I. Guido and F. Compagno and G. Garibotto and C. Klersy and E. Verrina and Ghiggeri, {G. M.} and M. Cardillo and P. Comoli and F. Ginevri",
note = "LR: 20170510; JID: 101627166; 0 (HLA Antigens); 0 (Isoantibodies); 80295-33-6 (Complement C1q); 80295-45-0 (Complement C3d); 2016/12/23 00:00 [received]; 2017/01/27 00:00 [revised]; 2017/02/13 00:00 [accepted]; 2017/04/04 06:00 [entrez]; 2017/04/04 06:00 [pubmed]; 2017/05/11 06:00 [medline]; ppublish",
year = "2017",
doi = "10.1155/2017/1747030 [doi]",
language = "English",
volume = "2017",
pages = "1747030",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Limited",

}

TY - JOUR

T1 - De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients

AU - Cioni, M.

AU - Nocera, A.

AU - Innocente, A.

AU - Tagliamacco, A.

AU - Trivelli, A.

AU - Basso, S.

AU - Quartuccio, G.

AU - Fontana, I.

AU - Magnasco, A.

AU - Drago, F.

AU - Gurrado, A.

AU - Guido, I.

AU - Compagno, F.

AU - Garibotto, G.

AU - Klersy, C.

AU - Verrina, E.

AU - Ghiggeri, G. M.

AU - Cardillo, M.

AU - Comoli, P.

AU - Ginevri, F.

N1 - LR: 20170510; JID: 101627166; 0 (HLA Antigens); 0 (Isoantibodies); 80295-33-6 (Complement C1q); 80295-45-0 (Complement C3d); 2016/12/23 00:00 [received]; 2017/01/27 00:00 [revised]; 2017/02/13 00:00 [accepted]; 2017/04/04 06:00 [entrez]; 2017/04/04 06:00 [pubmed]; 2017/05/11 06:00 [medline]; ppublish

PY - 2017

Y1 - 2017

N2 - De novo posttransplant donor-specific HLA-antibody (dnDSA) detection is now recognized as a tool to identify patients at risk for antibody-mediated rejection (AMR) and graft loss. It is still unclear whether the time interval from transplant to DSA occurrence influences graft damage. Utilizing sera collected longitudinally, we evaluated 114 consecutive primary pediatric kidney recipients grafted between 2002 and 2013 for dnDSA occurrence by Luminex platform. dnDSAs occurred in 39 patients at a median time of 24.6 months. In 15 patients, dnDSAs developed within 1 year (early-onset group), while the other 24 seroconverted after the first posttransplant year (late-onset group). The two groups were comparable when considering patient- and transplant-related factors, as well as DSA biological properties, including C1q and C3d complement-binding ability. Only recipient age at transplant significantly differed in the two cohorts, with younger patients showing earlier dnDSA development. Late AMR was diagnosed in 47% of the early group and in 58% of the late group. Graft loss occurred in 3/15 (20%) and 4/24 (17%) patients in early- and late-onset groups, respectively (p = ns). In our pediatric kidney recipients, dnDSAs predict AMR and graft loss irrespective of the time elapsed between transplantation and antibody occurrence.

AB - De novo posttransplant donor-specific HLA-antibody (dnDSA) detection is now recognized as a tool to identify patients at risk for antibody-mediated rejection (AMR) and graft loss. It is still unclear whether the time interval from transplant to DSA occurrence influences graft damage. Utilizing sera collected longitudinally, we evaluated 114 consecutive primary pediatric kidney recipients grafted between 2002 and 2013 for dnDSA occurrence by Luminex platform. dnDSAs occurred in 39 patients at a median time of 24.6 months. In 15 patients, dnDSAs developed within 1 year (early-onset group), while the other 24 seroconverted after the first posttransplant year (late-onset group). The two groups were comparable when considering patient- and transplant-related factors, as well as DSA biological properties, including C1q and C3d complement-binding ability. Only recipient age at transplant significantly differed in the two cohorts, with younger patients showing earlier dnDSA development. Late AMR was diagnosed in 47% of the early group and in 58% of the late group. Graft loss occurred in 3/15 (20%) and 4/24 (17%) patients in early- and late-onset groups, respectively (p = ns). In our pediatric kidney recipients, dnDSAs predict AMR and graft loss irrespective of the time elapsed between transplantation and antibody occurrence.

KW - Adolescent

KW - Age Factors

KW - Child

KW - Complement C1q/immunology

KW - Complement C3d/immunology

KW - Female

KW - Graft Rejection/immunology

KW - HLA Antigens/immunology

KW - Humans

KW - Isoantibodies/blood/immunology

KW - Kidney Transplantation/adverse effects

KW - Longitudinal Studies

KW - Male

KW - Retrospective Studies

KW - Risk Factors

KW - Tissue Donors

U2 - 10.1155/2017/1747030 [doi]

DO - 10.1155/2017/1747030 [doi]

M3 - Article

VL - 2017

SP - 1747030

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

ER -